DNA甲基化特征可准确区分胰腺癌与慢性胰腺炎的组织与血浆样本
研究在345份组织样本中分析DNA甲基化、信使RNA和微RNA水平以寻找区分胰腺导管腺癌(PDAC)与慢性胰腺炎(CP)的标志物,采用随机森林机器学习方法,并在48份样本中验证、16份液体活检样本中进一步佐证。6个DNA甲基化位点组成的特征在组织和血浆游离DNA中达到100%的验证诊断准确率。
要点
- 机器学习可定义区分PDAC与CP的标志物,低维嵌入和聚类分析未能做到。
- DNA甲基化诊断准确率最高,远超转录水平的重要性。
- 6个DNA甲基化位点特征在组织和血浆游离DNA中验证诊断准确率为100%。
核心结论
- 机器学习成功识别有效标志物特征,6个DNA甲基化位点特征在组织和血浆游离DNA中验证诊断准确率达100%。
- 该高诊断准确率一旦在更大疑似胰腺癌患者队列的液体活检样本中确认,可能对治疗成功产生巨大影响。
研究设计与样本
- 在345份组织样本中分析DNA甲基化、信使RNA和微RNA水平及其组合的全基因组变异以识别标志物。
- 采用随机森林机器学习方法提高诊断性能,结果在另外48份样本中验证,并在16份液体活检样本中进一步佐证。
主要发现
- 机器学习成功定义区分PDAC与CP的标志物,而低维嵌入和聚类分析未能做到。
- DNA甲基化诊断准确率最高,远超转录水平的重要性。
- 识别出的变化在公共数据库数据中得到确认,并在独立样本集中验证。
- 蛋白激酶Cβ型基因CpG岛中6个DNA甲基化位点的特征在组织和患者血浆游离DNA中验证诊断准确率为100%。
关键数值与推荐
- 6个DNA甲基化位点特征在组织和血浆游离DNA中验证诊断准确率为100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 液体活检样本数量仍然有限,结果需在更大疑似胰腺癌患者队列中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Differentiation from chronic pancreatitis (CP) is currently inaccurate in about one-third of cases. Misdiagnoses in both directions, however, have severe consequences for patients. We set out to identify molecular markers for a clear distinction between PDAC and CP. DESIGN: Genome-wide variations of DNA-methylation, messenger RNA and microRNA level as well as combinations thereof were analysed in 345 tissue samples for marker identification. To improve diagnostic performance, we established a random-forest machine-learning approach. Results were validated on another 48 samples and further corroborated in 16 liquid biopsy samples. RESULTS: Machine-learning succeeded in defining markers to differentiate between patients with PDAC and CP, while low-dimensional embedding and cluster analysis failed to do so. DNA-methylation yielded the best diagnostic accuracy by far, dwarfing the importance of transcript levels. Identified changes were confirmed with data taken from public repositories and validated in independent sample sets. A signature of six DNA-methylation sites in a CpG-island of the protein kinase C beta type gene achieved a validated diagnostic accuracy of 100% in tissue and in circulating free DNA isolated from patient plasma. CONCLUSION: The success of machine-learning to identify an effective marker signature documents the power of this approach. The high diagnostic accuracy of discriminating PDAC from CP could have tremendous consequences for treatment success, once the result from still a limited number of liquid biopsy samples would be confirmed in a larger cohort of patients with suspected pancreatic cancer.
引用
- Wu Y, Seufert I, Al-Shaheri FN, et al. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma. Gut. 2023. PMID: 37709492. doi:10.1136/gutjnl-2023-330155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。